Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates

Stock Track02-27

Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.

The sharp decline came after the company reported strong fourth-quarter results but issued full-year 2026 revenue guidance that fell short of analyst expectations. Aurinia posted Q4 earnings of $1.53 per diluted share, significantly beating the FactSet consensus estimate of $0.26, while revenue of $77.1 million also exceeded the $74.7 million forecast.

However, the company's outlook for 2026 total revenue in the range of $315 million to $325 million came in below the analyst consensus estimate of $326.8 million, prompting a sell-off as investors reacted to the guidance miss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109054506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109054506","market":"nz","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates","media":"Stock Track","content":"<p>Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.</p><p>The sharp decline came after the company reported strong fourth-quarter results but issued full-year 2026 revenue guidance that fell short of analyst expectations. Aurinia posted Q4 earnings of $1.53 per diluted share, significantly beating the FactSet consensus estimate of $0.26, while revenue of $77.1 million also exceeded the $74.7 million forecast.</p><p>However, the company's outlook for 2026 total revenue in the range of $315 million to $325 million came in below the analyst consensus estimate of $326.8 million, prompting a sell-off as investors reacted to the guidance miss.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 01:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.</p><p>The sharp decline came after the company reported strong fourth-quarter results but issued full-year 2026 revenue guidance that fell short of analyst expectations. Aurinia posted Q4 earnings of $1.53 per diluted share, significantly beating the FactSet consensus estimate of $0.26, while revenue of $77.1 million also exceeded the $74.7 million forecast.</p><p>However, the company's outlook for 2026 total revenue in the range of $315 million to $325 million came in below the analyst consensus estimate of $326.8 million, prompting a sell-off as investors reacted to the guidance miss.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1109054506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109054506","pubTimestamp":1772128603,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.The sharp decline came after the company reported strong fourth-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"个股追踪|2026年营收指引不及预期Aurinia制药盘中暴跌5.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.The sharp decline came after the company reported strong fourth-quarter results but issued full-year 2026 revenue guidance that fell short of analyst expectations. Aurinia posted Q4 earnings of $1.53 per diluted share, significantly beating the FactSet consensus estimate of $0.26, while revenue of $77.1 million also exceeded the $74.7 million forecast.However, the company's outlook for 2026 total revenue in the range of $315 million to $325 million came in below the analyst consensus estimate of $326.8 million, prompting a sell-off as investors reacted to the guidance miss.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109054506","isCrawlerRequest":true}